pmc logo image
Logo of brjclinpharmJournal URL: http://www.blackwellpublishing.com/journal.asp?ref=0306-5251
Journal List > Br J Clin Pharmacol > v.21(2); Feb 1986

Formats:
Br J Clin Pharmacol. 1986 February; 21(2): 223–226.
PMCID: PMC1400903
Copyright notice
A correlation between serum mebendazole concentrations and the aminopyrine breath test. Implications in the treatment of hydatid disease.
A Bekhti, J Pirotte, and R Woestenborghs
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
In 25 patients an [14C]-aminopyrine breath test (ABT) was performed immediately before the oral administration of 1.5-2 g of mebendazole three times daily. The concentration of mebendazole in serum was measured 2 h after each drug intake. A significant correlation was found between the results of ABT and the serum drug concentrations obtained after the second and third intake, as well as the highest concentration value. The ABT was repeated in six patients during a continuous treatment with mebendazole. In all of them this test indicated an increase in 14CO2 production with continued treatment. The results support the view that mebendazole is metabolized by the liver monooxygenase activity and behaves as an enzyme inducer.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (430K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 223
223
icon of scanned page 224
224
icon of scanned page 225
225
icon of scanned page 226
226
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Bekhti A. Mebendazole in toxocariasis. Ann Intern Med. 1984 Mar;100(3):463. [PubMed]
  • Braithwaite PA, Allan RJ, Dawson M, Roberts MS, Watson TR. Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease. Med J Aust. 1983 Oct 15;2(8):383–384. [PubMed]
  • Braithwaite PA, Roberts MS, Allan RJ, Watson TR. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol. 1982;22(2):161–169. [PubMed]
  • Bryceson AD, Woestenborghs R, Michiels M, van den Bossche H. Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease. Trans R Soc Trop Med Hyg. 1982;76(4):563–564. [PubMed]
  • Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975 Nov;83(5):632–638. [PubMed]
  • Michiels M, Hendriks R, Heykants J, van den Bossche H. The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther. 1982 Apr;256(2):180–191. [PubMed]
  • Münst GJ, Karlaganis G, Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol. 1980 May;17(5):375–378. [PubMed]
  • Pauwels S, Geubel AP, Dive C, Beckers C. Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci. 1982 Jan;27(1):49–56. [PubMed]
  • Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd. 1982;67(1):5–26. [PubMed]
  • Witassek F, Bircher J. Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol. 1983;25(1):85–90. [PubMed]
Articles from British Journal of Clinical Pharmacology are provided here courtesy of
British Pharmacological Society

PubMed articles by these authors